Overview: BCR-ABL Qualitative TestIntroduction: The BCR-ABL Qualitative Test detects gene changes linked to chronic myeloid leukemia, causing fatigue or frequent infections. Following 2023 NCCN guidelines, it uses PCR for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in molecular pathology for patients with suspected leukemia.
Other Names: BCR-ABL Gene Assay, CML Qualitative Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: BCR-ABL testing began in the 1980s with Philadelphia chromosome discovery. PCR assays emerged in the 1990s, and by the 2000s, qualitative PCR improved leukemia diagnosis.
Purpose: Diagnoses chronic myeloid leukemia, guides treatment, and confirms gene rearrangement in patients with fatigue or infections.
Test Parameters: 1. BCR-ABL Gene Rearrangement
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva at any time. Report symptoms like fatigue or infections, and list medications like tyrosine kinase inhibitors.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL bone marrow (EDTA), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document leukemia symptoms, family history of blood cancers, or prior chemotherapy. Include current medications, especially tyrosine kinase inhibitors.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for targeted therapy.
Procedural Considerations: Uses PCR to detect BCR-ABL gene rearrangement. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Improper storage or delayed transport can degrade DNA. Low sample quality may affect PCR sensitivity.
Clinical Significance: Positive results confirm CML, prompting tyrosine kinase inhibitor therapy. Negative results may require cytogenetic testing.
Specialist Consultation: Consult a hematologist for result interpretation. An oncologist referral is advised for treatment planning.
Additional Supporting Tests: BCR-ABL quantitative test, bone marrow biopsy, or FISH to confirm CML or assess disease extent.
Test Limitations: False negatives may occur with low-level gene rearrangements. Results require clinical correlation.
References: NCCN CML Guidelines, 2023; Blood, Baccarani M, 2022.
